GlassScriptPhysician profile
Kimberly Cecil
NPI 1124791405
$8,045.37
in general payments reported to CMS, 2019-2025
21 companies · $2,527 in 2025
The $2,527 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $270 · 2022: $1,589 · 2023: $733 · 2024: $2,926 · 2025: $2,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,110 · Travel and Lodging: $1,076.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,109.67 |
| Travel and Lodging | $1,076.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,976.53 | 2023-2025 | Wavewriter Alpha Prime 16, General - Pain Management, General - Therapies |
| Amgen INC. | $614.77 | 2021-2024 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $412.21 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $341.93 | 2022-2025 | |
| Ucb, INC. | $329.39 | 2021-2023 | Cimzia |
| Aurinia Pharma U.S., INC. | $276.57 | 2021-2023 | Lupkynis |
| Horizon Therapeutics Plc | $254.59 | 2022-2023 | Krystexxa |
| Octapharma USA, INC. | $164.82 | 2022-2024 | Octagam Immune Globulin (Human), Panzyga |
| Glaxosmithkline, LLC. | $130.71 | 2021-2024 | Benlysta |
| Painteq LLC | $128.85 | 2024 | Painteq |
| Lilly USA, LLC | $92.34 | 2021-2022 | |
| Janssen Biotech, INC. | $70.10 | 2022-2023 | Tremfya, Simponi Aria |
| Spr Therapeutics, INC | $68.09 | 2024-2025 | Sprint Pns System |
| Genentech, INC. | $31.48 | 2021 | |
| Medtronic, INC. | $31.35 | 2024 | Synchromedii |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $27.49 | 2023 | Intracept |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.76 | 2022 | |
| Genentech USA, INC. | $20.80 | 2023 | Actemra |
| Ibsa Pharma INC. | $18.81 | 2025 | Tirosint, Flector, Licart |
| Curonix LLC | $15.89 | 2023 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Mallinckrodt Hospital Products INC. | $14.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Cecil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.